Umoja BioPharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Umoja BioPharma, Inc. - overview
Established
2019
Location
Seattle, WA, US
Primary Industry
Pharmaceuticals
About
Established in 2019 and based in Washington, US, Umoja BioPharma, Inc. operates as a biopharmaceutical company. The company was founded by its CEO, Dr. Andrew Scharenberg, CTO, Dr.
Ryan Crisman, and Scientific Advisory Board Co-Chairs Michael Jensen and Philip Low. In January 2025, Umoja BioPharma, Inc. raised USD 100 million in series C funding co-led by new investor Double Point Ventures and returning investor Data Collective, with participation from other returning investors Cormorant Asset Management, MPM BioImpact, Qiming Venture Partners, RTW Investments, Alexandria Venture Investments, SB Investment Advisers, CaaS Capital Management, and Emerson Collective. New investors ARK Invest, K2 HealthVentures, Myeloma Investment Fund, University of Minnesota Foundation, and other unspecified investors also participated in the round.
Umoja BioPharma develops integrated cellular immunotherapy that helps in treating tumors through retooling a patient's immune system. The company has two lead pipeline programs under its portfolio: TumorTag UB-TT170 and VivoVec UB-VV100. TumorTag UB-TT170 is used for controlling folate receptors expressing solid tumors, and VivoVec UB-VV100 is being developed to treat patients with CD19+ hematological cancers. The company will use the January 2025 funding to support the development of its medical pipeline.
Current Investors
Qiming Venture Partners, MPM BioImpact, Casdin Capital
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Bioinformatics, Molecular Science, Genetics & Gene Therapy
Website
www.umoja-biopharma.com
Verticals
HealthTech
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.